syndrom
chronic
obstruct
pulmonari
diseas
copd
consist
chronic
bronchiti
cb
bronchiectasi
emphysema
revers
airway
diseas
combin
uniqu
individu
patient
older
patient
risk
copd
componentsfemphysema
cb
bronchiectasi
bacteri
viral
infect
play
role
acut
exacerb
copd
aecopd
acut
exacerb
cb
aecb
without
featur
copd
older
patient
risk
resist
bacteri
organ
episod
aecopd
aecb
organ
includ
morecommon
bacteria
implic
aecopd
aecb
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
lesscommon
nonenter
gramneg
organ
includ
pseudomona
aeruginosa
gramposit
organ
includ
staphylococcu
aureu
strain
nontuberculosi
mycobacteria
often
seen
aecopdaecb
episod
involv
elderli
patient
frequent
episod
cb
bronchiectasi
riskstratifi
antibiot
treatment
guidelin
appear
use
purul
episod
aecopd
episod
aecb
guidelin
prospect
valid
gener
popul
especi
elderli
popul
use
riskstratif
approach
elderli
patient
firstlin
antibiot
eg
amoxicillin
ampicillin
pivampicillin
trimethoprimsulfamethoxazol
doxycyclin
morelimit
spectrum
antibacteri
coverag
use
patient
like
low
probabl
resist
organ
aecopdaecb
secondlin
antibiot
eg
amoxicillinclavulan
acid
secondor
thirdgener
cephalosporin
respiratori
fluoroquinolon
broader
spectrum
coverag
reserv
patient
signific
risk
factor
resist
organ
fail
initi
antibiot
treatment
j
geriatr
soc
c
hronic
obstruct
pulmonari
diseas
copd
syndrom
compris
aspect
inflammatori
chronic
bronchiti
cb
includ
bronchiectasi
revers
airway
diseas
smallairway
obstruct
emphysema
secondari
lung
tissu
destruct
loss
lung
recoil
common
diseas
older
adult
individu
patient
uniqu
contribut
chronic
patholog
lung
statu
variou
diseas
compon
make
copd
variabl
contribut
individu
patient
clinic
manifest
particularli
note
interact
inflammatori
syndrom
cb
copd
cb
report
approxim
patient
sever
copd
syndrom
cb
also
occur
without
airway
obstruct
convers
minor
patient
cb
copd
coexist
smallairway
obstruct
featur
present
age
risk
factor
copd
cb
complex
process
age
contribut
risk
respiratori
infect
older
adult
agerel
chang
includ
risk
aspir
often
secondari
swallow
abnorm
loss
airway
protect
poor
nutrit
statu
obstruct
lung
process
mucou
plug
dynam
airway
collaps
weaker
respiratori
muscl
function
declin
innat
adapt
celland
humoralmedi
immun
poor
local
lung
immun
collect
respiratori
tract
infect
lead
caus
morbid
mortal
older
patient
acut
exacerb
copd
aecopd
thought
bacteri
viral
mix
viralbacteri
etiolog
mani
case
articl
review
epidemiolog
pathophysiolog
etiolog
clinic
featur
acut
exacerb
cb
aecb
aecopd
specif
focu
role
antibiot
treatment
elderli
patient
copd
signific
grow
caus
mortal
morbid
worldwid
estim
copd
fifth
lead
caus
worldwid
death
becom
third
lead
caus
age
world
popul
continu
use
tobacco
thought
respons
grow
burden
copd
use
global
initi
chronic
obstruct
lung
diseas
gold
criteria
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
symptom
cough
sputum
product
intern
studi
demonstr
odd
ratio
diagnosi
stage
ii
higher
copd
confid
interv
ci
per
increment
age
compar
develop
stage
ii
higher
copd
ci
packyear
smoke
adult
preval
found
larg
worldwid
studi
overal
men
women
stage
ii
higher
copd
normal
lung
age
result
obstruct
chang
caution
interpret
spirometri
older
adult
warrant
adjust
gold
criteria
made
suggest
patient
age
older
normal
fev
fvc
ratio
reduc
account
normal
age
process
inflammatori
immun
respons
inhal
toxic
particl
gase
tobacco
smoke
underli
current
theori
pathogenesi
copd
environment
type
inhal
injuri
airway
infect
genet
factor
defici
contribut
risk
develop
copd
although
inflammatori
chang
found
airway
smoker
suscept
minor
smoker
develop
copd
amplifi
inflammatori
immun
respons
respons
prolong
year
decad
link
lung
tissu
remodel
remodel
also
associ
cb
smallairway
bronchiol
result
air
flow
limit
lead
hyperinfl
lung
air
trap
copd
evid
support
concept
copd
diseas
acceler
lung
age
chronic
inflamm
grow
may
indic
futur
therapeut
approach
standard
definit
aecopd
includ
acut
sustain
worsen
patient
chronic
stabl
pulmonari
condit
beyond
normal
daytoday
variat
main
risk
factor
aecopd
lung
infect
secondari
risk
factor
includ
exposur
pollut
allergen
sed
congest
heart
failur
chf
pulmonari
embol
aecopd
associ
bacteri
airway
chang
approxim
half
case
viral
bacteri
mix
viralbacteri
chang
case
bacteria
airway
patient
aecopd
caus
releas
antigen
includ
endotoxin
peptidoglycan
fragment
lipoprotein
molecul
induc
potent
system
local
airway
inflammatori
effect
reduct
modul
viralor
bacterialinduc
inflamm
potenti
mitig
prevent
clinic
manifest
aecopd
multifactori
caus
may
also
precipit
aecopd
although
case
definit
caus
exacerb
determin
sever
limit
qualiti
life
qol
healthcar
cost
death
hospit
associ
aecopd
high
healthcar
cost
seen
even
diagnosi
copd
made
retrospect
analys
healthcar
cost
year
initi
diagnosi
copd
conduct
found
cost
diagnosi
higher
year
higher
year
match
control
data
estim
approxim
death
hospit
billion
direct
medic
expenditur
per
year
occur
unit
state
aecopd
aecopd
caus
progress
loss
lung
function
exacerb
annual
rate
declin
fev
approxim
greater
patient
copd
frequent
aecopd
less
frequent
rate
greater
frequenc
aecopd
associ
greater
use
healthcar
resourc
lower
qol
score
patient
copd
without
frequent
aecopd
risk
factor
frequent
aecopd
includ
older
age
sever
fev
impair
chronic
bronchial
mucu
hyperexcret
frequent
past
episod
aecopd
daili
cough
wheez
persist
symptom
cb
earli
studi
patient
copd
isol
bacteri
pathogen
sputum
rate
exacerb
stabl
diseas
caus
role
bacteria
question
recent
use
molecular
type
sputum
isol
nonencapsul
haemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
pseudomona
aeruginosa
new
strain
frequent
isol
aecopd
clinic
visit
without
exacerb
rel
exacerb
risk
ci
recent
cohort
subject
copd
age
ae
chronic
cough
sputum
product
consist
cb
found
significantli
morefrequ
aecopd
episod
requir
hospit
without
cb
cb
progress
diseas
character
chronic
sputum
product
defin
least
month
cough
sputum
consecut
year
elimin
tuberculosi
lung
cancer
caus
cough
cb
report
major
patient
copd
aecb
caus
recurr
attack
patient
associ
worsen
bronchial
inflamm
occur
averag
time
year
superimpos
baselin
cough
sputum
product
three
cardin
symptom
increas
daili
sputum
volum
chang
sputum
color
eg
darkerfmor
gray
yellow
green
worsen
dyspnea
defin
exacerb
found
patient
copd
aecb
two
three
previous
defin
symptom
better
clinic
outcom
fewer
clinic
failur
treat
antibiot
eg
amoxicillin
trimethoprimsulfamethoxazol
doxycyclin
placebo
metaanalysi
placebocontrol
trial
aecb
copd
found
overal
signific
benefit
antibiotictr
patient
recent
us
estim
suggest
adult
popul
cb
base
claim
data
patient
cb
sought
healthcar
treatment
estim
yearli
cost
billion
patient
age
older
million
patient
younger
unit
state
intern
aecb
result
million
annual
canadian
physician
visit
declin
lung
function
qol
seen
aecb
along
increas
patient
becom
housebound
report
impair
health
statu
result
increas
mortal
previous
note
older
age
risk
factor
greater
frequenc
aecopd
may
explain
worldwid
rise
copdassoci
hospit
risk
mortal
time
great
elderli
patient
admit
aecopd
younger
patient
patient
age
older
hospit
aecopd
rel
risk
death
shortli
discharg
compar
patient
younger
risk
develop
aecb
increas
age
particularli
comorbid
advanc
copd
malnutrit
recurr
aspir
cardiac
diseas
activ
smoke
recent
viral
infect
alcohol
impair
immun
function
chronic
lung
condit
resid
longterm
care
facil
preval
cb
unit
kingdom
also
increas
age
age
preval
per
increas
per
peopl
age
per
peopl
age
clinic
bronchiectasi
associ
chronic
product
cough
recurr
persist
infect
remodel
distort
conduct
airway
repeat
infect
profound
inflammatori
reaction
result
dilat
scar
bronchi
bronchiol
defin
bronchiectasi
postinfecti
state
eg
tuberculosi
necrot
pneumonia
fungal
diseas
idiopath
genet
disord
eg
primari
ciliari
dysfunct
cystic
fibrosi
alpha
defici
recurr
aspir
immun
defici
rheumatoid
arthriti
ulcer
coliti
allerg
bronchopulmonari
aspergillosi
known
caus
bronchiectasi
associ
bronchiectasi
copd
also
exist
one
studi
report
patient
copd
fev
less
evid
highresolut
chest
comput
tomographi
ct
bronchiectasi
patient
copd
ct
evid
bronchiectasi
clinic
moresever
episod
aecopd
preval
noncyst
fibrosi
bronchiectasi
unit
state
determin
estim
case
rang
case
person
age
case
age
older
preval
higher
women
men
age
patient
bronchiectasi
requir
averag
day
hospit
day
antibiot
therapi
higher
medic
care
expenditur
without
bronchiectasi
burden
bronchiectasi
signific
develop
countri
preval
burden
bronchiectasi
thought
even
greater
lessdevelop
countri
role
bacteria
much
morbid
mortal
copd
associ
aecopd
bacteria
thought
caus
half
episod
nonencapsul
h
influenza
catarrhali
pneumonia
repres
common
pathogen
bacteria
often
appear
center
complic
process
involv
amplif
inflamm
part
bacteri
antigen
stimul
inflammatori
mediat
previous
note
even
patient
copd
baselin
sputum
cultur
posit
h
influenza
catarrhali
pneumonia
pseudomona
use
molecular
type
techniqu
sputum
isol
aecopd
tend
demonstr
evid
new
strain
similar
aecopd
sever
potenti
trigger
aecb
identifi
includ
environment
condit
tobacco
smoke
lack
adher
copd
therapi
worsen
congest
heart
failur
chf
although
infect
includ
bacteria
virus
atyp
pathogen
like
caus
aecb
bacteri
infect
repres
major
caus
organ
sever
respiratori
virus
associ
approxim
exacerb
atyp
bacteria
mostli
chlamydia
pneumonia
implic
less
viral
pathogen
found
aecb
includ
influenza
parainfluenza
rhinoviru
coronaviru
adenoviru
respiratori
syncyti
viru
four
major
bacteri
caus
aecb
includ
elderli
patient
pneumonia
h
influenza
h
parainfluenza
catarrhali
less
commonli
staphylococcu
aureu
pseudomona
member
enterobacteriacea
famili
isol
aecb
studi
patient
requir
mechan
ventil
aecb
aecopd
report
frequent
isol
gramneg
enter
bacilli
pseudomona
stenotrophomona
spp
degre
measur
baselin
airway
obstruct
tend
predict
bacteri
organ
isol
sputum
obtain
aecb
patient
classifi
accord
baselin
fev
patient
lesssever
baselin
airway
obstruct
often
found
pneumonia
gramposit
cocci
wherea
moresever
baselin
airway
obstruct
associ
h
influenza
catarrhali
patient
worst
baselin
fev
greater
likelihood
pseudomona
enterobacteriacea
spp
isol
sputum
episod
aecbaecopd
patient
also
tend
risk
factor
gramneg
organ
sputum
includ
recent
hospit
use
mechan
ventil
frequent
sputum
patient
bronchiectasi
aecb
demonstr
nonenter
gramneg
bacteria
cultur
review
report
isol
sputum
h
influenza
pseudomona
aeruginosa
includ
mucoid
speci
catarrhali
pneumonia
aureu
mycobacterium
primarili
mycobacteriumavium
intracellular
complex
organ
patient
bronchiectasi
exacerb
pathogen
isol
patient
aecb
particularli
bronchiectasi
unfortun
often
demonstr
signific
antibiot
resist
pattern
penicillin
betalactam
macrolid
trimethoprim
sulfamethoxazol
sputum
isol
elderli
patient
also
result
frequent
drugresist
pathogen
multipl
drugresist
pneumonia
younger
patient
addit
aecbaecopd
older
patient
like
younger
patient
h
influenza
p
aeruginosa
cultur
sputum
fluoroquinoloneresist
pneumonia
strain
isol
patient
age
older
emerg
plasmidmedi
fluoroquinolon
gramneg
resist
worldwid
problem
diagnost
criteria
sever
aecb
aecopd
cardin
major
symptom
increas
sputum
volum
sputum
purul
worsen
dyspnea
use
classifi
clinic
sever
aecb
older
age
sever
underli
lung
diseas
associ
greater
frequenc
aecb
mostsever
aecb
label
type
three
major
symptom
present
type
ii
aecb
exhibit
two
three
major
symptom
type
iii
includ
one
symptom
least
one
minor
symptom
respiratori
tract
infect
occur
within
day
eg
increas
wheez
increas
cough
fever
increas
respiratori
heart
rate
argu
system
classifi
likelihood
bacteri
infect
caus
exacerb
realli
sever
scale
gold
guidelin
provid
spirometr
classif
diseas
sever
copd
use
guidelin
stage
mild
copd
fev
greater
predict
valu
stage
ii
moder
copd
fev
predict
valu
stage
iii
sever
copd
fev
predict
valu
stage
iv
mostsever
copd
fev
less
predict
valu
evid
chronic
respiratori
failur
fev
less
predict
valu
exacerb
copd
defin
chang
patient
baselin
dyspnea
cough
sputum
acut
onset
beyond
normal
daytoday
variat
diseas
gold
guidelin
stratifi
patient
aecopd
purul
sputum
base
presenc
three
cardin
symptom
increas
dyspnea
sputum
volum
sputum
purul
use
defin
episod
aecb
stratif
along
need
invas
noninvas
mechan
ventil
use
determin
need
choic
antibiot
base
potenti
pathogen
involv
aecopd
consider
like
organ
resist
pattern
like
organ
strategi
reduc
develop
resist
key
compon
consid
whether
antibiot
initi
older
patient
aecb
aecopd
evid
use
antibiot
patient
undergo
type
ii
aecb
exist
sever
guidelin
develop
aecb
use
risk
stratif
recommend
antibiot
guidelin
promot
elderli
patient
without
specif
data
popul
recent
review
intern
guidelin
antibacteri
treatment
aecb
base
risk
stratif
conclud
similar
canadian
thorac
societi
ct
develop
guidelin
base
riskstratif
system
three
categori
assess
treatment
patient
aecb
group
simpl
cb
describ
patient
age
demonstr
three
cardin
sign
bronchiti
sever
fewer
four
exacerb
per
year
fev
greater
predict
histori
cardiac
diseas
tabl
group
ii
complic
cb
describ
patient
meet
simpl
cb
group
criteria
plu
one
follow
risk
factor
fev
less
predict
valu
four
exacerb
per
year
histori
cardiac
diseas
supplement
oxygen
use
longterm
oral
corticosteroid
use
antibiot
use
within
previou
month
final
group
iii
chronic
suppur
categori
describ
patient
meet
criteria
group
ii
plu
chronic
purul
sputum
product
four
exacerb
per
year
requir
antibiot
four
time
per
year
often
within
previou
month
baselin
fev
less
predict
valu
may
multipl
risk
factor
tabl
prospect
studi
use
patient
stratif
defin
antibiot
treatment
aecb
demonstr
patient
complic
cb
exacerb
lower
clinic
microbiolog
success
rate
patient
simpl
uncompl
cb
exacerb
addit
classifi
aecb
ct
also
classifi
aecopd
purul
nonpurul
event
purul
aecopd
episod
defin
simpl
complic
exacerb
simpl
aecopd
increas
sputum
purul
dyspnea
wherea
complic
aecopd
featur
simpl
plu
least
one
follow
risk
factor
poor
outcom
fev
less
predict
four
exacerb
per
year
ischem
heart
diseas
use
home
oxygen
chronic
oral
steroid
use
tabl
summar
gold
guidelin
caus
organ
associ
aecopd
group
episod
mild
event
rare
requir
hospit
one
cardin
symptom
cb
risk
factor
poor
outcom
group
b
c
aecopd
like
requir
hospit
increasingli
sever
event
increas
risk
factor
poor
outcom
case
group
c
risk
factor
p
aeruginosa
signific
overlap
syndrom
aecopd
aecb
discuss
nonantibiot
treatment
approach
elderli
patient
combin
articl
acut
use
inhal
bronchodil
repres
mainstay
treatment
patient
evid
airway
obstruct
shortact
inhal
appear
prefer
initi
bronchodil
treatment
aecopd
although
prospect
placebocontrol
trial
perform
shortact
anticholinerg
agent
ipratropium
bromid
ad
treatment
regiment
metaanalysi
shown
aecopd
signific
differ
result
inhal
shortact
shortact
anticholinerg
although
commonli
use
combin
shortact
shortact
anticholinerg
uniformli
shown
improv
outcom
aecopd
nebulizerbas
deliveri
agent
appear
effect
use
metereddos
inhal
spacer
patient
aecopd
use
intraven
aminophyllin
methylxanthin
treatment
aecopd
controversi
consist
benefit
demonstr
frequent
presenc
comorbid
particularli
cardiovascular
comorbid
elderli
patient
aecopd
must
consid
use
highdos
inhal
treatment
intraven
methylxanthin
ensur
appropri
excess
hydrat
older
patient
exacerb
copd
cb
reduc
thick
sputum
aid
clearanc
supplement
oxygen
therapi
ensur
arteri
oxygen
tension
greater
mmhg
advoc
recent
metaanalysi
treatment
aecopd
demonstr
system
corticosteroid
effect
reduc
treatment
failur
use
noninvas
posit
pressur
ventil
reduc
need
intub
mortal
addit
chronic
use
bronchodil
inhal
corticosteroid
domiciliari
oxygen
therapi
shown
improv
surviv
copd
particip
pulmonari
rehabilit
improv
health
statu
elderli
patient
copd
cb
smoke
cessat
pneumococc
influenza
vaccin
also
import
prevent
measur
elderli
patient
copd
cb
intraven
replac
therapi
eg
immunoglobulin
g
antitrypsin
infus
use
patient
appropri
defici
bronchiectasi
data
elderli
patient
scarc
mechan
pharmacolog
techniqu
mobil
secret
patient
appear
import
adjunct
treatment
antibiot
treatment
elderli
patient
aecopd
aecb
use
riskstratif
approach
includ
comorbid
evalu
determin
recent
exposur
antibiot
appear
central
variou
guidelin
select
antibiot
treatment
episod
aecopd
aecb
unfortun
prospect
outcomebas
trial
yet
done
confirm
expert
consensu
guidelin
gener
subset
analys
elderli
patient
report
mani
recent
industrysponsor
noninferior
trial
bacteria
caus
mani
aecopd
episod
stress
approach
older
patient
aecopd
import
evalu
sever
exacerb
use
three
cardin
symptom
cbfincreas
sputum
volum
increas
purul
increas
dyspnea
baselin
furthermor
consider
underli
comorbid
underli
sever
lung
diseas
frequenc
exacerb
help
determin
whether
episod
simpl
complic
aecopd
tabl
outlin
riskstratifi
ct
guidelin
antibiot
treatment
patient
purul
sputumassoci
aecopd
recommend
case
simpl
aecopd
purul
sputum
treat
amoxicillin
secondor
thirdgener
cephalosporin
doxycyclin
extendedspectrum
macrolid
trimethoprimsulfamethoxazol
antibiot
treatment
recommend
purul
aecopd
classifi
complic
includ
respiratori
fluoroquinolon
gemifloxacin
levofloxacin
moxifloxacin
betalactambetalactamas
inhibitor
agent
amoxicillinclavulan
sputum
cultureguid
therapi
may
use
group
metaanalysi
random
control
trial
use
antibiot
aecopd
n
mean
age
conclud
antibiot
treatment
significantli
reduc
treatment
failur
inhospit
mortal
shortcours
antibiot
treatment
approach
day
evalu
metaanalysi
aecopd
aecb
short
cours
antibiot
effect
tradit
longer
treatment
cours
patient
mild
moder
aecopd
aecb
addit
acut
use
macrolid
antibiot
treatment
simpl
aecopd
associ
purul
sputum
chronic
use
macrolid
evalu
abil
immunomodul
potenti
prevent
aecopd
data
exist
support
use
prolong
macrolid
antibiot
number
chronic
inflammatori
lung
condit
diffus
panbronchiol
asthma
noncyst
fibrosisassoci
bronchiectasi
cystic
fibrosi
data
patient
copd
limit
somewhat
support
evalu
acut
bronchiti
aecopd
elderli
patient
averag
age
dutch
investig
found
gener
practition
prescrib
antibiot
major
case
acut
bronchiti
aecopd
prescrib
antibiot
elderli
patient
acut
bronchiti
associ
comorbid
condit
found
antibiot
often
prescrib
aecopd
patient
diabet
mellitu
heart
failur
author
call
practition
better
follow
publish
comorbid
riskstratifi
guidelin
would
greatli
limit
treatment
acut
bronchiti
antibiot
select
use
riskstratif
approach
involv
comorbid
analysi
advoc
treat
aecb
elderli
patient
similar
aecopd
riskstratificationbas
guidelin
treatment
aecb
treat
lowerrisk
patient
class
antibiot
narrow
spectrum
antibacteri
coverag
firstlin
sever
antibiot
guidelin
treatment
aecb
publish
consensusbas
guidelin
prospect
valid
specif
outcomebas
data
exist
older
patient
metaanalysi
compar
firstlin
secondlin
antibiot
treatment
aecb
mean
age
patient
random
control
trial
examin
rang
secondlin
antibiot
eg
amoxicillinclavulan
acid
secondor
thirdgener
cephalosporin
fluoroquinolon
effect
safe
firstlin
antibiot
eg
amoxicillin
ampicillin
pivampicillin
trimethoprimsulfamethoxazol
doxycyclin
moredetail
analysi
antibiot
effect
stratifi
accord
risk
factor
poor
outcom
includ
advanc
age
could
done
lack
data
anoth
metaanalysi
trial
compar
antibiot
treatment
aecb
found
macrolid
fluoroquinolon
amoxicillinclavulan
equival
shortterm
effect
although
use
fluoroquinolon
demonstr
better
microbiolog
success
fewer
recurr
aecb
macrolid
use
amoxicillinclavulan
found
associ
advers
effect
use
fluoroquinolon
macrolid
antibiot
risk
stratif
includ
age
could
done
third
metaanalysi
five
random
control
trial
use
semisynthet
penicillin
eg
amoxicillin
ampicillin
pivampicillin
trimethoprimbas
regimen
eg
trimethoprim
trimethoprimsulfamethoxazol
trimethoprimsulfadiazin
found
equival
effect
toxic
treat
aecb
variou
guidelin
treat
aecb
similar
recommend
current
ct
antibiot
guidelin
treat
aecb
summar
tabl
similar
antibiot
guidelin
aecopd
purul
sputum
tabl
specif
metaanalysi
random
control
trial
aecb
found
short
cours
antibiot
day
effect
safer
longdur
antimicrobi
treatment
antibiot
cours
short
day
shown
effect
longdur
cours
compar
antibiot
random
control
trial
earli
initi
antibiot
appear
import
patient
requir
hospit
antibiot
start
elderli
patient
averag
age
reach
hospit
hospit
aecb
aecopd
lower
shortterm
mortal
ct
guidelin
group
iii
suppur
cb
adjust
select
oral
parenter
antibiot
base
previou
current
sputum
cultur
result
appear
appropri
elderli
patient
bronchiectasi
frequent
p
aeruginosa
infect
patient
nonrespiratori
fluoroquinolon
ciprofloxacin
oral
intraven
togeth
intraven
antipseudomon
agent
frequent
prescrib
attempt
reduc
emerg
fluoroquinoloneresist
p
aeruginosa
organ
inhal
tobramycin
lack
food
drug
administr
approv
lack
proven
efficaci
patient
noncyst
fibrosi
bronchiectasi
specialti
consult
often
requir
treat
elderli
patient
bronchiectasi
isol
nontuberculosi
mycobacteria
tabl
summar
recent
random
control
compar
antibiot
trial
treatment
aecb
trial
design
noninferior
trial
part
industri
sponsor
three
trial
enrol
patient
mean
age
older
two
trial
demonstr
statist
differ
outcom
review
recent
trial
moxifloxacin
shown
small
significantli
better
clinic
cure
rate
compar
antibiot
aecb
studi
show
interv
next
exacerb
moxifloxacin
second
trial
gemifloxacin
also
demonstr
small
statist
better
clinic
cure
rate
compar
antibiot
hospit
patient
aecb
gemifloxacin
treatment
associ
reduct
hospit
limit
size
studi
tabl
lack
detail
risk
stratif
limit
number
older
patient
make
direct
applic
result
older
patient
difficult
select
antibiot
treatment
elderli
patient
aecb
sever
consider
beyond
use
riskstratifi
guidelin
must
made
potenti
alter
pharmacokinet
pharmacodynam
agent
result
diseaseor
agerel
decreas
renal
metabol
drug
clearanc
potenti
drug
interact
must
evalu
final
antibiot
select
well
special
monitor
dose
requir
must
care
consid
potenti
complex
older
patient
copd
syndrom
uniqu
patient
consist
element
cb
bronchiectasi
emphysema
revers
airway
diseas
elderli
patient
high
risk
copd
cb
bronchiectasi
episod
aecopd
aecb
associ
viral
bacteri
atyp
organ
along
environment
factor
act
trigger
elderli
patient
also
greater
risk
resist
bacteri
organ
multipl
drugresist
pneumonia
nonenter
gramneg
organ
h
influenza
stenotrophomona
spp
p
aeruginosa
although
prospect
valid
riskstratifi
antibi
otic
guidelin
appear
help
direct
treatment
aecopd
aecb
specif
design
age
popul
antibiot
riskstratifi
guidelin
gener
consensu
process
specif
design
elderli
popul
recent
antibiot
studi
report
specif
outcom
elderli
patient
often
noninferioritydesign
studi
small
number
subject
gener
antibiot
treatment
aecopd
aecb
appear
benefici
warrant
individu
patient
may
need
moreaggress
comprehens
care
work
direct
specif
antibiot
therapi
elderli
patient
experienc
aecopd
aecb
need
establish
valid
outcomebas
riskstratifi
antibiot
guidelin
popul
optim
strategi
manag
aecopd
aecb
requir
longterm
intervent
studi
aim
prevent
frequent
acut
exacerb
hospit
would
like
thank
lisa
pastor
outstand
editori
contribut
manuscript
conflict
interest
author
indic
follow
relationship
timothi
albertsonfspeak
honorarium
boehring
ingelheim
glaxosmithklin
topic
copd
w
dose
clavulan
alway
specifi
az
azithromycin
moxifloxacin
amoxicillin
cl
clarithromycin
ceft
ceftriaxon
l
levofloxacin
ac
amoxicillinclavulan
cef
cefuroxim
g
gemifloxacin
qd
daili
tid
three
time
daili
bid
twice
daili
uc
uncompl
chronic
bronchiti
cb
complic
chronic
bronchiti
cc
clinic
curefp
protocol
rrr
relaps
respons
rate
ns
signific
ae
advers
event
exten
extend
releas
schere
plough
topic
aecb
research
grant
pfizer
ventilatorassoci
pneumonia
samuel
louiefspeak
honorarium
boehring
ingelheim
astra
zeneca
topic
copd
andrew
chanfspeak
honorarium
franc
foundat
intermun
topic
idiopath
pulmonari
fibrosi
author
contribut
timothi
albertson
concept
literatur
research
write
samuel
louie
write
andrew
chan
concept
write
sponsor
role
sponsor
